youtube_live
Q3 2026 earnings • released • EPS beat +११.३८% • Revenue beat +७.३३%
See resultschevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
US$ ३१.२७
arrow_upward
+६.३२%(+१.८६) 1D
नोभेम्बर ९, १५:३१:०१ GMT-५ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
US$ २९.३२
High
US$ ३१.४१
Low
US$ २८.९३
Mkt. cap
१.८७ अरब
Avg. vol.
१२.९३ लाख
Volume
५.९४ लाख
52-wk high
US$ ४६.००
52-wk low
US$ २२.२४
EPS
-US$ ७.०१
Beta
०.६६
Shares outstanding
५.९८ करोड
No. of employees
५४०
Open
US$ २९.३२
High
US$ ३१.४१
Low
US$ २८.९३
Mkt. cap
१.८७ अरब
Avg. vol.
१२.९३ लाख
Volume
५.९४ लाख
52-wk high
US$ ४६.००
52-wk low
US$ २२.२४
EPS
-US$ ७.०१
Beta
०.६६
Shares outstanding
५.९८ करोड
No. of employees
५४०
News stories
From web sources and news partners
shattered.io
·
१३ मिनेट पहिले
Stacey Cunningham: 1st Woman NYSE Chief Bullish [2026]
Bloomberg.com
·
९ मिनेट पहिले
Watch 95% S&P 500, 5% Bitcoin in New Franklin ETF: Drilldown
The Defiant
·
५ मिनेट पहिले
Anthropic to Launch Nasdaq IPO Tuesday, IFR Reports
Seeking Alpha
·
१ घण्टा पहिले
What Happened To The November Time Target? (SP500)
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc